PAVmed Inc (PAVM) News & Events

$4.920

-0.146 (-2.96%)At close

PAVM News

2.008-15NASDAQ.COM

PAVmed (PAVM) Q2 2026 Earnings Call Transcript

9.508-15Yahoo Finance

PAVmed Q2 2026 Business Update Highlights Progress Across Portfolio

9.508-14Yahoo Finance

PAVmed Reports Q2 2026 Financial Results with Reduced Losses

9.508-14PRnewswire

PAVmed Provides Business Update and Q2 Financial Results

9.508-13PRnewswire

Lucid Diagnostics Reports Q2 2026 Financial Results and Business Update

8.508-05PRnewswire

Concert Policy Recognizes EsoGuard® as Only Esophageal Precancer Test

1.008-04PRnewswire

Lucid Diagnostics to Participate in Upcoming Investor Conferences

1.007-31PRnewswire

PAVmed to Host Business Update Conference Call on August 14

1.007-30PRnewswire

Lucid Diagnostics to Host Business Update Conference Call

9.505-15seekingalpha

PAVmed Q1 2026 Earnings Call Insights

Show More News

PAVM Events

8/5 09:00

Lucid Diagnostics' EsoGuard Test Recognized by Concert Coverage Policy

Lucid Diagnostics (LUCD), a subsidiary of PAVmed (PAVM), announced that Concert, a healthcare technology company recently acquired by Lyric, issued a positive coverage policy effective July 2026 for non-invasive screening of esophageal precancer and cancer. Concert establishes coverage policies that its client health plans can adopt. The policy cites sufficient evidence in published guidelines and peer-reviewed literature to definitively demonstrate improved health outcomes, and considers Lucid's EsoGuard Esophageal DNA Test medically necessary in patients who meet American College of Gastroenterology screening criteria.

7/16 10:00

PAVmed Trading Halted Due to Volatility

PAVmed trading halted, volatility trading pause

7/16 10:00

PAVmed Trading Resumes

PAVmed trading resumes

5/15 08:10

PAVmed Reports Q1 Revenue of $22 Million

Reports Q1 revenue $22,000 vs. $8,000 last year. PAVmed had cash and cash equivalents of $6.5M as of March 31, compared to $1.5M as of December 31, 2025. "PAVmed now has a significantly simplified capital structure and strengthened balance sheet, positioning the Company to focus on execution across our core businesses and evaluate additional asset acquisition opportunities aligned with our long-term growth strategy," said Lishan Aklog, PAVmed's Chairman and CEO. "Veris continues to expand its commercial engagement with OSU-The James while progressing development of its implantable physiological monitor toward FDA submission, and Lucid continues to build commercial momentum for EsoGuard with a strengthened balance sheet pending Medicare coverage. We are also actively advancing multiple technologies within our relaunched medical device portfolio under Joseph Virgilio's leadership, while increasingly leveraging his experience building and scaling growth-stage businesses."

4/21 06:10

PAVmed Files to Sell 9.23M Shares of Common Stock

PAVmed files to sell 9.23M shares of common stock for holders

Show More Events

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.